Amal Therapeutics announces the signature of an Exclusive Patent License Agreement with the University of Minnesota
Geneva, Switzerland, October 27, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties. View PDF
Amal Therapeutics and the Oslo University Hospital announce research collaboration agreement for cancer immunotherapy validation
Geneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional […]
Amal Therapeutics to publish R&D findings in Cancer Research
Geneva, Switzerland, June 26, 2015 – Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, will be available on-line on the Cancer Research website on Friday June 26, 2015. View PDF


You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: